Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21800783 | 0.90 | BACE1 (0.34) | SLC2A1BACE1KDM4ENPC1RAB9A | |
| SCHEMBL1583415 | 0.85 | BACE1 (0.37) | SLC2A1BACE1KDM4ENPC1RAB9A | |
| SCHEMBL1083353 | 0.84 | RAB9A (0.36) | SLC2A1BACE1KDM4ENPC1RAB9A | |
| SCHEMBL1072471 | 0.84 | RAB9A (0.36) | SLC2A1BACE1KDM4ENPC1RAB9A | |
| SCHEMBL21800693 | 0.83 | BACE1 (0.34) | SLC2A1BACE1KDM4ENPC1RAB9A | |
| SCHEMBL1072580 | 0.80 | RAB9A (0.36) | BACE1KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL17114933 | 0.80 | P2RX3 (0.45) | SLC2A1BACE1KDM4ENPC1RAB9A | |
| SCHEMBL13395391 | 0.80 | P2RX3 (0.45) | SLC2A1BACE1KDM4ENPC1RAB9A | |
| SCHEMBL1068681 | 0.75 | KDM4E (0.36) | SLC2A1BACE1KDM4ENPC1RAB9A | |
| SCHEMBL17099108 | 0.74 | CYP2D6 (0.34) | KDM4ENPC1RAB9AL3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | SLC2A1 3533/4885BACE1 1197/4885KDM4E 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.